[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"severe-eosinophilic-asthma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:severe-eosinophilic-asthma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100641542","phase-4-fasenra-an-asthma-study-100641542",false,"NCT07654842","Fasenra: An Asthma Study","Fasenra Demonstrates Durability Over the Full 8-week Treatment Period","Inclusion Criteria:\n\n1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF.\n2. At least 18 years of age at the time of signing the informed consent at Visit 1.\n3. Documented asthma diagnosis ≥12 months prior to Visit 1. This may be documented by physician-diagnosis or by documented pharmacy records.\n4. Treated with a daily ICS-containing maintenance inhaler for asthma at a stable dose for ≥3 months prior to Visit 1. This inhaler may contain ICS alone, or in combination with a LABA or LABA-LAMA. The prescribed inhaler must be compatible with a study-provided EMM (see Appendix A).\n5. Prescribed a SABA-containing reliever inhaler, AND willing to use study-provided ICS-SABA reliever with EMM provided by the study.\n6. Prescribed benralizumab for severe eosinophilic asthma for ≥6 months AND has had ≥4 benralizumab doses (3 loading doses + at least 1 8-week dosing interval).\n\nExclusion Criteria:\n\n1. Current smoker (including tobacco, vaping, and marijuana). Former smokers must have stopped ≥6 months prior to Visit 1.\n2. Has a known, preexisting, clinically significant cardiac, endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, hematological, or any other system abnormalities that are uncontrolled with standard treatment, which, in the investigator's opinion, would compromise the participant's safety, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence.\n3. History of use of any biologic therapy for asthma (other than benralizumab) within 5 half-lives or 5 months, whichever is longer, before Visit 1.\n4. A severe asthma exacerbation within 4 weeks of Visit 1. For this study, a severe asthma exacerbation is defined as an episode of worsening asthma symptoms that result in at least one of the following:\n\n   * Use of systemic corticosteroids for at least 3 consecutive days (or a single depo-injectable dose of corticosteroids)\n   * An inpatient hospitalization (defined as admission to an inpatient facility and\u002For evaluation and treatment in a healthcare facility for ≥24 hours) due to asthma\n   * An emergency department visit (defined as evaluation and treatment for \\\u003C24 hours in an emergency department or urgent care) due to asthma that required systemic corticosteroids (as per above)\n5. Current enrollment in an asthma-related clinical trial.\n6. Any known history of adverse reactions to budesonide-albuterol.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this observational study is to learn more about the effectiveness of benralizumab (Fasenra, 30 mg every 8 weeks) in maintaining asthma control in people with severe eosinophilic asthma.\n\nParticipants will have electronic medication monitors fitted to their usual maintenance inhaler, as well as a study-provided anti-inflammatory rescue inhaler, albuterol-budesonide (AirSupra). These monitors will track when each inhaler is used. Participants will also upload time-stamped photos of their benralizumab administration to their electronic medical records.",[26,27,28,29],"Eosinophilic Asthma","Severe Asthma","Severe Eosinophilic Asthma","Asthma","NOT_YET_RECRUITING","2026-06-12",{"date":33,"type":34},"2026-06-17","ACTUAL",{"date":36,"type":20},"2026-07-01",{"date":38,"type":20},"2028-01-01",{"name":40,"class":41},"Endeavor Health","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100609451","a-real-life-observational-study-in-severe-eosinophilic-asthma-adult-participant-treated-with-benralizumab-in-italy-100609451","NCT07214753","A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy","ItAlian, Multicenter, Observational, Prospective sTudy to Evaluate the acHievement of Clinical rEmission and immuNomodulation in Severe Eosinophilic Asthma Patients Treated With Benralizumab - the ATHENA Study","ATHENA","Inclusion Criteria:\n\n* Adults (≥ 18 years old) diagnosed with severe uncontrolled eosinophilic asthma.\n* Benralizumab has been prescribed according to the approved label and local reimbursement criteria\n* Provision of signed Informed Consent Form (ICF) prior to any study-related activities\n* Benralizumab has been initiated within 7 days prior to study enrollment or is planned to be initiated within 7 days after enrollment (in the latter case, provided that the decision to prescribe benralizumab is made prior to the decision to enroll the patient in the study).\n\nExclusion Criteria:\n\n* Benralizumab treatment within the 12 months prior to study enrollment and up to 8 days before enrollment\n* Previous participation (in the 12 months before enrollment), current participation or plan to participate within the follow up period to any other clinical trial.\n* Contraindication to benralizumab as per current Summary of Product Characteristics (SmPC).\n* Pregnant or lactating women.\n* patients with any clinical condition that may interfere with the subject's ability to cooperate and comply with the study procedures based on the Investigator's judgement.\n* Previous or concomitant use of omalizumab, reslizumab, dupilumab, tezepelumab or mepolizumab without washout period as per clinical practice",{"count":52,"type":20},335,"OBSERVATIONAL","This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.",[28],"RECRUITING","2026-06-11",{"date":31,"type":34},{"date":60,"type":34},"2025-12-20",{"date":62,"type":20},"2028-12-31",{"name":64,"class":65},"AstraZeneca","INDUSTRY",28]